MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
Key Highlights
- ➤Cash $287.7M as of September 30, 2026; runway guidance extends through 2028
- ➤MacroGenics (MGNX) reports $20.1M third-quarter net loss versus $16.8M profit
- ➤MGC028 Phase 1 dose escalation completed; randomized two-dose evaluation planned by year-end
- ➤Gilead option exercise generated a $10.0M payment under the collaboration agreement
- ➤Quarterly revenue fell to $18.7M from $53.0M year over year
Expert Statements
Eric Risser, President and Chief Executive Officer of MacroGenics
“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months.”
Eric Risser, President and Chief Executive Officer of MacroGenics
“We are grateful to our employees and partners for their dedication and contributions to this progress. Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation.”
* Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels * Reported interim results at ESMO in both Phase 1 study of MGC026 in heavily pretreated SCCHN patients and Phase 2 study of lorigerlimab in CCGC patients * First patient dosed with MGC030 in Phase 1 study * Strengthened Board with addition of two new independent directors with expertise in oncology drug discovery and development * Cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026; cash runway guidance remains through 2028 ROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended September 30, 2026, and highlighted recent corporate progress.
Get started
Create a free account to read the full story.